TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms.
暂无分享,去创建一个
Angela G. Fleischman | B. Druker | M. Deininger | A. Agarwal | R. Silver | H. Pahl | M. Loriaux | K. Aichberger | T. O'hare | C. L. Petersen | R. Press | Fei Yang | G. Bagby | A. Fleischman | Samuel B. Luty | T. Bumm | Shirin Doratotaj | Kavin B. Vasudevan | D. Latocha | Curtis L. Petersen | Dorian H Latocha
[1] Angela G. Fleischman,et al. The stem cell fitness landscape and pathways of molecular leukemogenesis. , 2011, Frontiers in bioscience.
[2] P. Campbell,et al. JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. , 2010, Blood.
[3] Erin F. Simonds,et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. , 2010, Blood.
[4] B. Druker,et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. , 2010, Blood.
[5] Michael G. Kharas,et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. , 2010, Cancer cell.
[6] Jane Yates,et al. TLR8-dependent TNF-(alpha) overexpression in Fanconi anemia group C cells. , 2009, Blood.
[7] Andrew Collins,et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms , 2009, Nature Genetics.
[8] A. Tefferi,et al. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients , 2009, Leukemia.
[9] O. Kilpivaara,et al. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science , 2008, Leukemia.
[10] David A. Williams,et al. TNF-α induces leukemic clonal evolution ex vivo in Fanconi anemia group C murine stem cells , 2007 .
[11] D. Gilliland,et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations , 2007, Leukemia.
[12] David A. Williams,et al. References Subscriptions Permissions Email Alerts Inflammatory Reactive Oxygen Species-Mediated Hemopoietic Suppression in Fancc-Deficient Mice , 2013 .
[13] David A. Williams,et al. TNF-alpha induces leukemic clonal evolution ex vivo in Fanconi anemia group C murine stem cells. , 2007, The Journal of clinical investigation.
[14] D. Gilliland,et al. TG 101209 , a small molecule JAK 2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK 2 V 617 F and MPL W 515 L / K mutations , 2007 .
[15] P. Campbell,et al. The myeloproliferative disorders. , 2006, The New England journal of medicine.
[16] B. Druker,et al. Characterization of murine JAK2V617F-positive myeloproliferative disease. , 2006, Cancer research.
[17] A. Tefferi. Pathogenesis of myelofibrosis with myeloid metaplasia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] P. Campbell,et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.
[19] L. Sabatier,et al. Tumor necrosis factor alpha induces senescence and chromosomal instability in human leukemic cells , 2004, Oncogene.
[20] F. Rosselli,et al. Abnormal lymphokine production: a novel feature of the genetic disease Fanconi anemia , 1992, Human Genetics.
[21] V. Poggi,et al. TNF-alpha and IFN-gamma are overexpressed in the bone marrow of Fanconi anemia patients and TNF-alpha suppresses erythropoiesis in vitro. , 2003, Blood.
[22] B. Aggarwal. Signalling pathways of the TNF superfamily: a double-edged sword , 2003, Nature Reviews Immunology.
[23] I. Dybedal,et al. Self-Renewal of Multipotent Long-Term Repopulating Hematopoietic Stem Cells Is Negatively Regulated by FAS and Tumor Necrosis Factor Receptor Activation , 2001, The Journal of experimental medicine.
[24] I. Dybedal,et al. Tumor necrosis factor (TNF)-mediated activation of the p55 TNF receptor negatively regulates maintenance of cycling reconstituting human hematopoietic stem cells. , 2001, Blood.
[25] M. Lensch,et al. Selective pressure as an essential force in molecular evolution of myeloid leukemic clones: a view from the window of Fanconi anemia , 1999, Leukemia.
[26] M. Buchwald,et al. Multiple inhibitory cytokines induce deregulated progenitor growth and apoptosis in hematopoietic cells from Fac-/- mice. , 1998, Blood.
[27] F. Rosselli,et al. Abnormal lymphokine production: a novel feature of the genetic disease Fanconi anemia. II. In vitro and in vivo spontaneous overproduction of tumor necrosis factor alpha. , 1994 .
[28] N. Shahidi,et al. Tumor necrosis factor‐α overproduction in Fanconi's anemia , 1993 .
[29] Birnie Gd,et al. The HL60 cell line: a model system for studying human myeloid cell differentiation. , 1988, The British journal of cancer. Supplement.
[30] R. Ohno,et al. Effect of recombinant human tumor necrosis factor on the colony growth of human leukemia progenitor cells and normal hematopoietic progenitor cells. , 1987, Blood.
[31] D. Williams,et al. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma. , 1986, Journal of immunology.